NASDAQ:FATE • US31189P1021
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for FATE THERAPEUTICS INC (FATE).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-10-31 | HC Wainwright & Co. | Upgrade | Neutral -> Buy |
| 2025-10-27 | Needham | Reiterate | Hold -> Hold |
| 2025-10-27 | Wedbush | Upgrade | Neutral -> Outperform |
| 2025-08-13 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-06-12 | Needham | Reiterate | Hold -> Hold |
| 2025-05-14 | Needham | Reiterate | Hold -> Hold |
| 2025-05-14 | Barclays | Maintains | Overweight -> Overweight |
| 2025-05-14 | Baird | Maintains | Neutral -> Neutral |
| 2025-03-06 | Needham | Reiterate | Hold -> Hold |
| 2025-03-06 | Stifel | Maintains | Hold -> Hold |
| 2025-03-06 | Wedbush | Reiterate | Neutral -> Neutral |
| 2025-03-06 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2024-11-19 | Needham | Reiterate | Hold |
| 2024-11-13 | Needham | Reiterate | Hold |
| 2024-08-22 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-08-14 | Needham | Reiterate | Hold |
| 2024-06-17 | Piper Sandler | Upgrade | Neutral -> Overweight |
| 2024-05-16 | HC Wainwright & Co. | Maintains | Neutral -> Neutral |
| 2024-05-10 | BMO Capital | Maintains | Market Perform -> Market Perform |
| 2024-05-10 | Wedbush | Maintains | Neutral -> Neutral |
| 2024-05-10 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-05-10 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2024-05-06 | Wedbush | Reiterate | Neutral -> Neutral |
| 2024-04-23 | Wedbush | Reiterate | Neutral -> Neutral |
| 2024-04-11 | Needham | Reiterate | Hold |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 63.533M -34.03% | 13.631M -78.55% | 6.646M -51.24% | 5.588M -15.92% | 4.823M -13.69% | 7.276M 50.86% | 61.926M 751.10% | 179.92M 190.54% | 286.59M 59.29% | 390.51M 36.26% | 505.82M 29.53% | |
| EBITDA YoY % growth | -172.229M 41.54% | -176.577M -2.52% | -134.803M 23.66% | -146.192M -8.45% | -163.062M -11.54% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -190.511M 38.22% | -195.539M -2.64% | -147.704M 24.46% | -156.087M -5.68% | -171.059M -9.59% | -206.626M -20.79% | -175.68M 14.98% | -108.769M 38.09% | 25.092M 123.07% | 120.63M 380.75% | 229.5M 90.25% | |
| Operating Margin | -299.86% | -1,434.52% | -2,222.45% | -2,793.24% | -3,546.74% | -2,839.83% | -283.69% | -60.45% | 8.76% | 30.89% | 45.37% | |
| EPS YoY % growth | -1.64 43.64% | -1.64 | -1.15 29.88% | -1.17 -1.39% | -1.14 1.92% | -1.21 -5.70% | -1.15 5.06% | -0.58 49.78% | 0.18 131.86% | 0.90 391.67% | 1.64 81.92% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.29 10.75% | -0.29 -0.59% | -0.30 -9.26% | -0.30 -10.44% | -0.28 2.86% | -0.29 0.70% | -0.30 -0.27% | -0.30 -1.94% |
| Revenue Q2Q % growth | 1.082M -33.58% | 1.082M -43.26% | 1.082M -37.85% | 1.082M -20.96% | 897.6K -17.04% | 612K -43.44% | 612K -43.44% | 612K -43.44% |
| EBITDA Q2Q % growth | -27.887M 26.51% | -33.742M -11.15% | -39.545M -58.84% | -48.858M -123.91% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -37.855M 8.30% | -38.971M -5.42% | -40.755M -17.33% | -41.66M -19.99% | -39.521M -4.40% | -40.653M -4.32% | -42.605M -4.54% | -45.102M -8.26% |
All data in USD
18 analysts have analysed FATE and the average price target is 5.04 USD. This implies a price increase of 306.72% is expected in the next year compared to the current price of 1.24.
FATE THERAPEUTICS INC (FATE) will report earnings on 2026-05-06.
The consensus EPS estimate for the next earnings of FATE THERAPEUTICS INC (FATE) is -0.29 USD and the consensus revenue estimate is 1.08M USD.
The expected long term growth rate for FATE THERAPEUTICS INC (FATE) is 3.37%.